Document Basket

Saved pages

Saved documents

Please note: This information is saved in a cookie. In case your browser deletes cookies after a session, the information will be lost.

DKSH and Eli Lilly and Company enter partnership in Singapore January 17, 2020


			
				DKSH and Eli Lilly and Company enter partnership in Singapore

DKSH has become a strategic partner for Lilly, a global healthcare leader to sell, market and distribute Lilly’s brands in Singapore.

Media release

DKSH and Eli Lilly and Company enter partnership in Singapore

DKSH has become a strategic partner for Lilly, a global healthcare leader to sell, market and distribute Lilly’s brands in Singapore.

Singapore, January 17, 2020 – DKSH has sealed a strategic partnership with Eli Lilly and Company, a global healthcare leader and significant contributor to the healthcare industry in the Singapore market.

 

DKSH manages a range of over 15 brands from Lilly, mainly in the areas of oncology, diabetes, central nervous system (CNS), musculoskeletal and autoimmune diseases. This partnership expands the sales coverage, brand focus and depth of customer engagement to bring the benefits of Lilly’s products to the many patients it serves.

 

“DKSH and Lilly share the vision and values to work together in bringing an innovative pipeline of products to more patients. With our in-depth knowledge of the local market as well as marketing and sales capabilities, DKSH will expand the access to reliable and affordable healthcare in Singapore,” said Dr. Varun Sethi, Vice President, Healthcare, Southeast Asia & Vietnam.

 

Rehan Saghir, General Manager for Lilly, ASEAN, added: “Lilly has many years of experience working with DKSH across ASEAN. Through this partnership, Lilly will strengthen its presence in Singapore. Together with DKSH, we look forward to expanding the access of Lilly products and to continuing to launch Lilly’s innovative therapies in the fields of diabetes, oncology as well as immunology and pain in Singapore for the years to come.”